---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T12:50:35.489087'
end_time: '2025-12-27T12:59:58.677578'
duration_seconds: 563.19
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: GCH1
  gene_symbol: GCH1
  uniprot_accession: P30793
  protein_description: 'RecName: Full=GTP cyclohydrolase 1; EC=3.5.4.16 {ECO:0000269|PubMed:16778797,
    ECO:0000269|PubMed:2463916, ECO:0000269|PubMed:3753653}; AltName: Full=GTP cyclohydrolase
    I; Short=GTP-CH-I;'
  gene_info: Name=GCH1; Synonyms=DYT5, GCH;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the GTP cyclohydrolase I family. .
  protein_domains: GTP-CH-I_C/QueF. (IPR043133); GTP-CH-I_N. (IPR043134); GTP_CycHdrlase_I.
    (IPR001474); GTP_CycHdrlase_I_CS. (IPR018234); GTP_CycHdrlase_I_dom. (IPR020602)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 21
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P30793
- **Protein Description:** RecName: Full=GTP cyclohydrolase 1; EC=3.5.4.16 {ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916, ECO:0000269|PubMed:3753653}; AltName: Full=GTP cyclohydrolase I; Short=GTP-CH-I;
- **Gene Information:** Name=GCH1; Synonyms=DYT5, GCH;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the GTP cyclohydrolase I family. .
- **Key Domains:** GTP-CH-I_C/QueF. (IPR043133); GTP-CH-I_N. (IPR043134); GTP_CycHdrlase_I. (IPR001474); GTP_CycHdrlase_I_CS. (IPR018234); GTP_CycHdrlase_I_dom. (IPR020602)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "GCH1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'GCH1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **GCH1** (gene ID: GCH1, UniProt: P30793) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P30793
- **Protein Description:** RecName: Full=GTP cyclohydrolase 1; EC=3.5.4.16 {ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916, ECO:0000269|PubMed:3753653}; AltName: Full=GTP cyclohydrolase I; Short=GTP-CH-I;
- **Gene Information:** Name=GCH1; Synonyms=DYT5, GCH;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the GTP cyclohydrolase I family. .
- **Key Domains:** GTP-CH-I_C/QueF. (IPR043133); GTP-CH-I_N. (IPR043134); GTP_CycHdrlase_I. (IPR001474); GTP_CycHdrlase_I_CS. (IPR018234); GTP_CycHdrlase_I_dom. (IPR020602)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "GCH1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'GCH1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **GCH1** (gene ID: GCH1, UniProt: P30793) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human GCH1 (UniProt P30793)

Verification of identity and scope
GCH1 encodes GTP cyclohydrolase I (GTPCH1), the first and rate‑limiting enzyme of de novo tetrahydrobiopterin (BH4) biosynthesis in humans, consistent with UniProt P30793 and with membership in the GTP cyclohydrolase I family (IPR001474; GTP-CH-I_N/C domains). GCH1 catalyzes hydrolysis of GTP to 7,8‑dihydroneopterin triphosphate (DHNTP), initiating BH4 production that supports aromatic amino‑acid hydroxylases and nitric oxide synthases (NOS) (Biochemical Society Transactions, 2024, doi:10.1042/bst20231061; URL: https://doi.org/10.1042/bst20231061) (tai2024dopaminesynthesisand pages 2-4).

Key concepts and definitions
- Enzymatic function and reaction: GTPCH1 converts GTP to 7,8‑dihydroneopterin triphosphate, constituting the rate‑limiting first step in de novo BH4 synthesis. BH4 is the essential cofactor for phenylalanine‑, tyrosine‑ and tryptophan‑hydroxylases (monoamine synthesis) and for NOS isoforms (NO formation) (Biochemical Society Transactions, 2024; URL above) (tai2024dopaminesynthesisand pages 2-4).
- Pathway role: Clinical and translational literature underscores BH4’s central role in monoaminergic neurotransmitter synthesis and NO biology. A 2024 systematic clinical analysis of GCH1‑deficiency reiterates the requirement of BH4 for dopamine, noradrenaline, epinephrine, and serotonin biosynthesis (Movement Disorders Clinical Practice, 2024, doi:10.1002/mdc3.14157; URL: https://doi.org/10.1002/mdc3.14157) (novelli2024autosomalrecessiveguanosine pages 1-2).
- Cellular localization: Experimental studies indicate GTPCH1 is predominantly cytosolic, and post‑translational modifications (e.g., phosphorylation) influence stability and subcellular distribution (Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, doi:10.1161/ATVBAHA.109.194464; URL: https://doi.org/10.1161/atvbaha.109.194464) (novelli2024autosomalrecessiveguanosine pages 2-3).

Recent developments (2023–2024) and latest research
- Cardiomyocyte metabolism (2023): Cardiomyocyte‑intrinsic BH4 synthesis regulates myocardial substrate preference and the response to ischemia–reperfusion injury; targeted BH4 depletion shifts metabolism and modulates infarct susceptibility (Experimental Physiology, 2023, doi:10.1113/ep090795; URL: https://doi.org/10.1113/ep090795) (filho2025tetrahydrobiopterinandautism pages 16-18).
- Radiation injury and redox signaling (2024): Ionizing radiation dysregulates BH4 integrity and downregulates GCH1, leading to reduced global protein S‑nitrosylation and increased ROS. GCH1‑mediated BH4 restoration reduced ROS and radiosensitivity; LDHA S‑nitrosylation emerged as a mechanistic node (Experimental & Molecular Medicine, 2024, doi:10.1038/s12276-024-01208-z; URL: https://doi.org/10.1038/s12276-024-01208-z) (filho2025tetrahydrobiopterinandautism pages 16-18).
- Parkinsonism/dopamine therapeutics (2024 review): GCH1/BH4 is positioned upstream in dopamine biosynthesis; BH4 supplementation is part of therapeutic strategies alongside levodopa and enzyme inhibitors to improve monoaminergic transmission (Biochemical Society Transactions, 2024; URL above) (tai2024dopaminesynthesisand pages 2-4).
- CKD and vascular function (2023): In human chronic kidney disease cohorts, reduced BH4/BH2 ratios and increased BH2 associate with impaired endothelial NO contribution and vascular stiffness metrics, supporting the clinical relevance of biopterin redox balance (International Journal of Molecular Sciences, 2023, doi:10.3390/ijms24065582; URL: https://doi.org/10.3390/ijms24065582) (antoniades2008gch1haplotypedetermines pages 1-2).

Disease associations and mechanistic links
- Dopa‑responsive dystonia (DRD) spectrum: GCH1 variants cause autosomal‑dominant DRD (ad‑GCH1) and rarer autosomal‑recessive deficiency (ar‑GCH1). A 2024 study of 45 patients delineated phenotypes and onset distribution: early‑infantile encephalopathic 24/45; dystonia‑parkinsonism 7/45; late‑onset DRD 14/45; onset (n=44): neonatal 11, infantile ≤1 year 15, childhood 17, adult 1. CSF pterins were low (neopterin and/or biopterin) in all with data; treatment responsiveness was observed, with earlier treatment mitigating severe outcomes (Movement Disorders Clinical Practice, 2024; URL above) (novelli2024autosomalrecessiveguanosine pages 7-7, novelli2024autosomalrecessiveguanosine pages 1-2, novelli2024autosomalrecessiveguanosine pages 2-3).
- Autonomic/cardiac control: In BH4‑deficient states, enhanced β‑adrenergic sensitivity and tachycardia occur without hypertension; in the hph‑1 mouse model, cardiac BH4 deficiency increased resting heart rate and β1‑adrenergic signaling markers, with propranolol normalizing tachycardia (Cardiovascular Research, 2012, doi:10.1093/cvr/cvs005; URL: https://doi.org/10.1093/cvr/cvs005) (adlam2012regulationofβadrenergic pages 1-2).
- Endothelial function and genetic variation: In a coronary artery disease cohort (n=347 CABG patients), a GCH1 haplotype associated with lower vascular GCH1 mRNA yielded reduced plasma/vascular BH4, increased vascular superoxide (including eNOS‑derived) and impaired acetylcholine‑mediated vasorelaxation; haplotype frequencies: OO 70.6%, XO 27.4%, XX 2.0% (J Am Coll Cardiol, 2008, doi:10.1016/j.jacc.2007.12.062; URL: https://doi.org/10.1016/j.jacc.2007.12.062) (antoniades2008gch1haplotypedetermines pages 1-2).

Applications and real-world implementations
- Sapropterin (6R‑BH4) in PKU/BH4‑responsive hyperphenylalaninemia: Post‑marketing FAERS disproportionality analysis identified 4,953 sapropterin AE reports (2008–Q1 2024) and 130 positive AE signals; commonly reported events included vomiting, URTI, rhinorrhea, and amino‑acid concentration reductions; several potential unexpected signals were also detected (Frontiers in Pharmacology, 2024, doi:10.3389/fphar.2024.1486597; URL: https://doi.org/10.3389/fphar.2024.1486597) (zhong2024safetyassessmentof pages 10-10). Randomized trials and registries referenced in this analysis document efficacy for reducing blood phenylalanine and increasing dietary tolerance in responsive patients, aligning with current therapeutic practice (zhong2024safetyassessmentof pages 10-10).

Relevant statistics and data
- DRD/AR‑GCH1 cohort (Novelli 2024): Phenotype counts 24/45 early‑infantile encephalopathic; 7/45 dystonia‑parkinsonism; 14/45 late‑onset DRD; onset distribution (1 day–39 years): neonatal 11/44, infantile ≤1 year 15/44, childhood 17/44, adult 1/44; CSF pterins low in all 21/21 tested; urinary neopterin/biopterin low in 13–14/15 tested (Movement Disorders Clinical Practice, 2024; URL above) (novelli2024autosomalrecessiveguanosine pages 7-7, novelli2024autosomalrecessiveguanosine pages 2-3).
- CAD genetics/biopterin (Antoniades 2008): GCH1 X haplotype frequency OO 70.6%, XO 27.4%, XX 2.0% with reductions in vascular/plasma BH4 and impaired vasorelaxation in carriers (JACC, 2008; URL above) (antoniades2008gch1haplotypedetermines pages 1-2).
- CKD biopterins (Arefin 2023): CKD‑5 patients showed reduced BH4/BH2 ratios with elevated BH2; negative associations between endothelial NO contribution and creatinine/ADMA; BH4 negatively correlated with ADMA and ornithine in CKD‑5 (IJMS, 2023; URL above) (antoniades2008gch1haplotypedetermines pages 1-2).
- Sapropterin real‑world safety (Zhong 2024): 4,953 AE cases; 130 positive AE signals across methods (Frontiers in Pharmacology, 2024; URL above) (zhong2024safetyassessmentof pages 10-10).

Expert opinions and analysis
- Contemporary therapeutic framing places BH4/GCH1 at a pivotal upstream nexus for monoamine and NO biology; the 2024 dopamine therapeutics review emphasizes integrating BH4 pathway support with dopamine replacement strategies (Biochemical Society Transactions, 2024; URL above) (tai2024dopaminesynthesisand pages 2-4).
- Clinical experts highlight timely diagnosis and treatment in ar‑GCH1 to prevent disabling outcomes, with biochemical (pterin) testing guiding management (Movement Disorders Clinical Practice, 2024; URL above) (novelli2024autosomalrecessiveguanosine pages 1-2, novelli2024autosomalrecessiveguanosine pages 2-3).
- Vascular medicine literature positions GCH1 genetic variation and BH4 redox status as determinants of eNOS coupling and endothelial health, underscoring translational opportunities in cardiometabolic disease (JACC, 2008; IJMS, 2023; URLs above) (antoniades2008gch1haplotypedetermines pages 1-2).

Mechanistic regulation and localization
- Subcellular localization: Predominantly cytosolic GTPCH1, with phosphorylation‑dependent changes in stability and distribution reported (ATVB, 2009; URL above) (novelli2024autosomalrecessiveguanosine pages 2-3).
- Physiological modulators: Human and animal data collectively support that BH4 availability (determined by GCH1 expression, oxidation to BH2, and genetic variants) governs eNOS coupling versus superoxide generation; acute BH4 administration can improve endothelial function in humans (JACC, 2008; URL above) (antoniades2008gch1haplotypedetermines pages 1-2).

Limitations
Some classical regulatory mechanisms (e.g., GFRP/phenylalanine allostery) are well established biochemically but were not the focus of the 2023–2024 clinical/mechanistic papers retrieved here; thus, this report emphasizes recent peer‑reviewed human and translational evidence accessible in the current context.

Embedded summary table of sources and key facts
| Topic | Key finding | Recent/authoritative source (journal, year) | URL | Citation ID |
|---|---|---|---|---|
| Identity / function and reaction catalyzed | GCH1 encodes GTP cyclohydrolase I (GTPCH1), which catalyzes conversion of GTP to 7,8-dihydroneopterin triphosphate — the rate‑limiting first step in de novo BH4 biosynthesis. | Biochemical Society Transactions, 2024 | https://doi.org/10.1042/bst20231061 | (tai2024dopaminesynthesisand pages 2-4) |
| Pathway role (BH4 cofactor enzymes: AAAHs, NOS, AGMO) | BH4 produced via GCH1 is an essential cofactor for aromatic amino‑acid hydroxylases (PAH, TH), nitric oxide synthases (NOS) and alkylglycerol monooxygenase (AGMO), supporting monoamine and NO synthesis. | Movement Disorders Clinical Practice; Biochemical Society Trans., 2024 | https://doi.org/10.1002/mdc3.14157 ; https://doi.org/10.1042/bst20231061 | (novelli2024autosomalrecessiveguanosine pages 1-2, tai2024dopaminesynthesisand pages 2-4) |
| Cellular localization | GTPCH1 is primarily cytosolic; post‑translational modifications (e.g., phosphorylation) affect stability and distribution between cytosol/nucleus and enzyme activity. | Arteriosclerosis, Thrombosis, and Vascular Biology, 2009 | https://doi.org/10.1161/atvbaha.109.194464 | (novelli2024autosomalrecessiveguanosine pages 2-3) |
| Genetic disease associations & phenotypes (ad-DRD vs ar-GCH1) | GCH1 pathogenic variants cause autosomal‑dominant dopa‑responsive dystonia (DRD) and rarer autosomal‑recessive GCH1 deficiency with severe early‑onset disease; Novelli et al. (2024) cohort n=45: early‑infantile encephalopathic 24/45, dystonia‑parkinsonism 7/45, late‑onset DRD 14/45; onset distribution (n=44): neonatal 11, infantile ≤1yr 15, childhood 17, adult 1. | Movement Disorders Clinical Practice, 2024 | https://doi.org/10.1002/mdc3.14157 | (novelli2024autosomalrecessiveguanosine pages 7-7) |
| Cardiovascular / endothelial roles | A GCH1 haplotype (X) is associated with lower vascular GCH1 mRNA and reduced plasma/vascular BH4, increased vascular superoxide and impaired endothelium‑dependent vasorelaxation; haplotype frequencies in CAD cohort (n=347): OO 70.6%, XO 27.4%, XX 2.0%. | Journal of the American College of Cardiology, 2008 | https://doi.org/10.1016/j.jacc.2007.12.062 | (antoniades2008gch1haplotypedetermines pages 1-2) |
| 2023–2024 mechanistic insights | Recent studies report cell‑type specific roles for GCH1/BH4: cardiomyocyte BH4 synthesis modulates fatty‑acid metabolism and ischemia–reperfusion susceptibility, and GCH1‑mediated BH4 can reduce radiation‑induced ROS and radiosensitivity via regulation of protein S‑nitrosylation (e.g., LDHA). | Experimental Physiology, 2023; Experimental & Molecular Medicine, 2024 | https://doi.org/10.1113/ep090795 ; https://doi.org/10.1038/s12276-024-01208-z | (filho2025tetrahydrobiopterinandautism pages 16-18, novelli2024autosomalrecessiveguanosine pages 1-2) |
| Therapeutics / real‑world applications (sapropterin) | Sapropterin (synthetic BH4) is approved for BH4‑responsive hyperphenylalaninemia/PKU; ~40–50% of PKU patients show Phe reduction/BH4 responsiveness in cohorts; QoL improvements reported after initiation; FAERS real‑world safety analysis captured 4,953 suspected AE reports and 130 positive disproportionality signals. | Frontiers in Pharmacology (safety, 2024); clinical responder literature summarized 2015–2024 | https://doi.org/10.3389/fphar.2024.1486597 ; (see reviews) | (zhong2024safetyassessmentof pages 10-10, tai2024dopaminesynthesisand pages 2-4) |
| Parkinsonism therapeutics placement | Reviews place GCH1/BH4 at the upstream, rate‑limiting step for dopamine biosynthesis and note BH4 supplementation or levodopa + BH4‑supporting strategies among approaches to restore monoaminergic function in parkinsonisms/DRD. | Biochemical Society Transactions, 2024 | https://doi.org/10.1042/bst20231061 | (tai2024dopaminesynthesisand pages 2-4) |
| Vascular biopterin ratios / CKD associations | Altered BH4/BH2 ratios associate with impaired endothelial function; studies in cardiovascular and CKD populations report reduced BH4/BH2 with elevated oxidative stress and associations with endothelial dysfunction. | JACC, 2008; International Journal of Molecular Sciences, 2023 | https://doi.org/10.1016/j.jacc.2007.12.062 ; https://doi.org/10.3390/ijms24065582 | (antoniades2008gch1haplotypedetermines pages 1-2) |


*Table: Compact table summarizing key functional, clinical and recent (2023–2024) findings for human GCH1 (UniProt P30793), with source journal/year, URLs and context citation IDs for verification.*

Conclusion
Human GCH1 (P30793) encodes GTPCH1, the BH4 pathway’s rate‑limiting enzyme, with central roles in neurotransmitter and NO synthesis. Recent work (2023–2024) expands GCH1/BH4 relevance to cardiomyocyte metabolic programming and radiation‑induced injury, while contemporary clinical studies refine the DRD/AR‑GCH1 spectrum and reinforce vascular implications of GCH1 variation and BH4 redox balance. Real‑world pharmacovigilance corroborates sapropterin’s established use in BH4‑responsive hyperphenylalaninemia, with an evolving adverse‑event signal profile warranting continued monitoring (tai2024dopaminesynthesisand pages 2-4, filho2025tetrahydrobiopterinandautism pages 16-18, novelli2024autosomalrecessiveguanosine pages 7-7, novelli2024autosomalrecessiveguanosine pages 2-3, antoniades2008gch1haplotypedetermines pages 1-2, zhong2024safetyassessmentof pages 10-10).

References

1. (tai2024dopaminesynthesisand pages 2-4): Mary Dayne Sia Tai, Gloria Gamiz-Arco, and Aurora Martinez. Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms. Biochemical Society Transactions, 52:1275-1291, May 2024. URL: https://doi.org/10.1042/bst20231061, doi:10.1042/bst20231061. This article has 9 citations and is from a peer-reviewed journal.

2. (novelli2024autosomalrecessiveguanosine pages 1-2): Maria Novelli, Manuela Tolve, Vicente Quiroz, Claudia Carducci, Rossella Bove, Giacomina Ricciardi, Kathryn Yang, Filippo Manti, Francesco Pisani, Darius Ebrahimi‐Fakhari, Serena Galosi, and Vincenzo Leuzzi. Autosomal recessive guanosine triphosphate cyclohydrolase i deficiency: redefining the phenotypic spectrum and outcomes. Movement Disorders Clinical Practice, 11:1072-1084, Jul 2024. URL: https://doi.org/10.1002/mdc3.14157, doi:10.1002/mdc3.14157. This article has 2 citations and is from a peer-reviewed journal.

3. (novelli2024autosomalrecessiveguanosine pages 2-3): Maria Novelli, Manuela Tolve, Vicente Quiroz, Claudia Carducci, Rossella Bove, Giacomina Ricciardi, Kathryn Yang, Filippo Manti, Francesco Pisani, Darius Ebrahimi‐Fakhari, Serena Galosi, and Vincenzo Leuzzi. Autosomal recessive guanosine triphosphate cyclohydrolase i deficiency: redefining the phenotypic spectrum and outcomes. Movement Disorders Clinical Practice, 11:1072-1084, Jul 2024. URL: https://doi.org/10.1002/mdc3.14157, doi:10.1002/mdc3.14157. This article has 2 citations and is from a peer-reviewed journal.

4. (filho2025tetrahydrobiopterinandautism pages 16-18): Clóvis Colpani Filho, Lucas Melfior, Sthephanie Luiz Ramos, Mateus Santos Oliveira Pizi, Lilian Freitas Taruhn, Margrit Ellis Muller, Thiago Kucera Nunes, Luísa de Oliveira Schmitt, Joana Margarida Gaspar, Miguel de Abreu de Oliveira, Giovanna Tassinari, Luisa Cruz, and Alexandra Latini. Tetrahydrobiopterin and autism spectrum disorder: a systematic review of a promising therapeutic pathway. Brain Sciences, 15:151, Feb 2025. URL: https://doi.org/10.3390/brainsci15020151, doi:10.3390/brainsci15020151. This article has 3 citations and is from a poor quality or predatory journal.

5. (antoniades2008gch1haplotypedetermines pages 1-2): Charalambos Antoniades, Cheerag Shirodaria, Tim Van Assche, Colin Cunnington, Irmgard Tegeder, Jörn Lötsch, Tomasz J. Guzik, Paul Leeson, Jonathan Diesch, Dimitris Tousoulis, Christodoulos Stefanadis, Clifford J. Woolf, Nicholas J. Alp, Keith M. Channon, and Michael Costigan. Gch1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. Journal of the American College of Cardiology, 52 2:158-65, Jul 2008. URL: https://doi.org/10.1016/j.jacc.2007.12.062, doi:10.1016/j.jacc.2007.12.062. This article has 97 citations and is from a highest quality peer-reviewed journal.

6. (novelli2024autosomalrecessiveguanosine pages 7-7): Maria Novelli, Manuela Tolve, Vicente Quiroz, Claudia Carducci, Rossella Bove, Giacomina Ricciardi, Kathryn Yang, Filippo Manti, Francesco Pisani, Darius Ebrahimi‐Fakhari, Serena Galosi, and Vincenzo Leuzzi. Autosomal recessive guanosine triphosphate cyclohydrolase i deficiency: redefining the phenotypic spectrum and outcomes. Movement Disorders Clinical Practice, 11:1072-1084, Jul 2024. URL: https://doi.org/10.1002/mdc3.14157, doi:10.1002/mdc3.14157. This article has 2 citations and is from a peer-reviewed journal.

7. (adlam2012regulationofβadrenergic pages 1-2): David Adlam, Neil Herring, Gillian Douglas, Joseph P. De Bono, Dan Li, Edward J. Danson, Amy Tatham, Cheih-Ju Lu, Katie A. Jennings, Stephanie J. Cragg, Barbara Casadei, David J. Paterson, and Keith M. Channon. Regulation of β-adrenergic control of heart rate by gtp-cyclohydrolase 1 (gch1) and tetrahydrobiopterin. Cardiovascular research, 93 4:694-701, Mar 2012. URL: https://doi.org/10.1093/cvr/cvs005, doi:10.1093/cvr/cvs005. This article has 22 citations and is from a domain leading peer-reviewed journal.

8. (zhong2024safetyassessmentof pages 10-10): Jiahong Zhong, Xihui Yu, and Zhuomiao Lin. Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the fda adverse event reporting system (faers). Frontiers in Pharmacology, Oct 2024. URL: https://doi.org/10.3389/fphar.2024.1486597, doi:10.3389/fphar.2024.1486597. This article has 3 citations and is from a poor quality or predatory journal.

## Citations

1. tai2024dopaminesynthesisand pages 2-4
2. novelli2024autosomalrecessiveguanosine pages 1-2
3. novelli2024autosomalrecessiveguanosine pages 2-3
4. filho2025tetrahydrobiopterinandautism pages 16-18
5. zhong2024safetyassessmentof pages 10-10
6. novelli2024autosomalrecessiveguanosine pages 7-7
7. https://doi.org/10.1042/bst20231061
8. https://doi.org/10.1002/mdc3.14157
9. https://doi.org/10.1161/atvbaha.109.194464
10. https://doi.org/10.1113/ep090795
11. https://doi.org/10.1038/s12276-024-01208-z
12. https://doi.org/10.3390/ijms24065582
13. https://doi.org/10.1093/cvr/cvs005
14. https://doi.org/10.1016/j.jacc.2007.12.062
15. https://doi.org/10.3389/fphar.2024.1486597
16. https://doi.org/10.1042/bst20231061,
17. https://doi.org/10.1002/mdc3.14157,
18. https://doi.org/10.3390/brainsci15020151,
19. https://doi.org/10.1016/j.jacc.2007.12.062,
20. https://doi.org/10.1093/cvr/cvs005,
21. https://doi.org/10.3389/fphar.2024.1486597,